Patient-specific Neoantigen-MHC complex (null)

Patient-specific Neoantigen-MHC complex refers to the unique complex formed by binding of a tumor-derived peptide neoantigen to a specific MHC molecule (encoded by a patient's HLA genotype). These complexes are not present in normal tissues and result from individual tumor mutations, gene fusions, aberrant splicing, or post-translational modifications[1][3][5]. They are displayed on the surface of antigen-presenting cells and/or tumor cells, where they can be recognized by specific T cell receptors, triggering a potent immune response. As each patient’s tumor mutations are unique, each patient has a distinct set of possible neoantigen-MHC complexes, which form the basis for highly individualized immunotherapeutic approaches such as personalized cancer vaccines and engineered T-cell therapies[1][2][4][5]. This complex is at the intersection of molecular oncology, immunology, and personalized medicine. Its identification relies on sequencing and bioinformatic prediction combined with experimental validation, and its therapeutic targeting is at the cutting edge of cancer immunotherapy research and clinical translation[1][2][3][4][5].

Other names

neoepitope-MHC complexneoantigen-HLA complexpatient-specific neoantigen-MHCneoantigenome

Induction of tumor-specific cytotoxic T lymphocyte (CTL) response through presentation of immunogenic neoantigen on MHC to T cell receptor Activation and priming of CD8+ and CD4+ T cells